Strategy for identifying dendritic cell-processed CD4+ T cell epitopes from the HIV Gag p24 protein by Bozzacco, Leonia et al.
Rockefeller University 
Digital Commons @ RU 
Publications Steinman Laboratory Archive 
2012 
Strategy for identifying dendritic cell-processed CD4+ T cell 




Follow this and additional works at: https://digitalcommons.rockefeller.edu/steinman-publications 
Recommended Citation 
Bozzacco, L., H. Yu, J. Dengjel, C. Trumpfheller, H. A. Zebroski III, N. Zhang, V. Küttner, et al. 2012. 
"Strategy for Identifying Dendritic Cell-Processed CD4+ T Cell Epitopes from the HIV Gag p24 Protein." 
PLoS ONE 7 (7) 
This Article is brought to you for free and open access by the Steinman Laboratory Archive at Digital Commons @ 
RU. It has been accepted for inclusion in Publications by an authorized administrator of Digital Commons @ RU. 
For more information, please contact nilovao@rockefeller.edu. 
Strategy for Identifying Dendritic Cell-Processed CD4+ T
Cell Epitopes from the HIV Gag p24 Protein
Leonia Bozzacco1*, Haiqiang Yu2¤a, Jörn Dengjel3,4, Christine Trumpfheller1, Henry A. Zebroski III2,
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Abstract
Mass Spectrometry (MS) is becoming a preferred method to identify class I and class II peptides presented on major
histocompability complexes (MHC) on antigen presenting cells (APC). We describe a combined computational and MS
approach to identify exogenous MHC II peptides presented on mouse spleen dendritic cells (DCs). This approach enables
rapid, effective screening of a large number of possible peptides by a computer-assisted strategy that utilizes the extraordinary
human ability for pattern recognition. To test the efficacy of the approach, a mixture of epitope peptide mimics (mimetopes)
from HIV gag p24 sequence were added exogenously to Fms-like tyrosine kinase 3 ligand (Flt3L)-mobilized splenic DCs. We
identified the exogenously added peptide, VDRFYKTLRAEQASQ, and a second peptide, DRFYKLTRAEQASQ, derived from the
original exogenously added 15-mer peptide. Furthermore, we demonstrated that our strategy works efficiently with HIV gag
p24 protein when delivered, as vaccine protein, to Flt3L expanded mouse splenic DCs in vitro through the DEC-205 receptor.
We found that the same MHC II-bound HIV gag p24 peptides, VDRFYKTLRAEQASQ and DRFYKLTRAEQASQ, were naturally
processed from anti-DEC-205 HIV gag p24 protein and presented on DCs. The two identified VDRFYKTLRAEQASQ and
DRFYKLTRAEQASQ MHC II-bound HIV gag p24 peptides elicited CD4+ T-cell mediated responses in vitro. Their presentation by
DCs to antigen-specific T cells was inhibited by chloroquine (CQ), indicating that optimal presentation of these exogenously
added peptides required uptake and vesicular trafficking in mature DCs. These results support the application of our strategy
to identify and characterize peptide epitopes derived from vaccine proteins processed by DCs and thus has the potential to
greatly accelerate DC-based vaccine development.
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Introduction
Cellular immune responses against any foreign non-self antigens
depend upon recognition of peptides presented on the surface of
antigen presenting cells (APCs), such as dendritic cells (DCs) [1].
Antigenic peptides are derived from the processing of exogenous
proteins and are presented on MHC II molecules that are
abundantly expressed on DCs [2]. Studies analyzing antigen
presentation generally require the use of antigen-specific T cells
isolated from immunized animals or human volunteers. Indeed, T
cell epitopes are defined by screening sets of partially overlapping
synthetic peptides covering the entire sequence of the known
antigenic protein [3], or covering the entire proteome if no protein
antigen is known. However, disadvantages of using T cell based-
assays are the difficulty in quantitating peptides presented on the
MHC complex by an absolute measurement and the large number
of peptides that need to be assayed [4].
Other approaches for identification of T cell epitopes use
predictive computational models of MHC binding affinity to
obtain candidate peptides [5]. To date many epitopes have been
identified using HLA binding motifs and peptide prediction
algorithms. For example, Assarsson et al. [6] identified 54 novel
epitopes from more than 4000 computer-defined peptides with
HLA binding motifs, including 38 that were CD8+ T cell specific.
However, it is not known whether these are immunodominant or
subdominant within any given CD8+ T cell response.
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Mass spectrometry (MS) provides an effective means to sample
and quantitate MHC II-associated self- peptides from DCs for
many MHC II proteins [7,8]. Here we seek to identify among the
total mixture of MHC II peptides the specific antigenic peptides of
low abundance derived from exogenous proteins. Due to the
limited dynamic range of MS instrumentation, typically only a
small fraction of the observed peptides in a complex sample is
successfully sequenced, even with the fastest current instruments
[9]. Targeted data acquisition approaches have been shown to
achieve much lower detection limits [10], but only a limited
number of peptides can be targeted in any given analysis. Thus,
current data-dependent analysis will not consistently capture the
peptides of interest, and targeted data acquisition cannot
effectively cover the large number of possibilities.
Here, we solved this problem by a four step-approach
(Figure 1B). First, we enumerate all theoretical possible MHC-II
peptides from the exogenously added protein sequence. Second,
we obtain mass spectra of the enriched MHC II peptides from
DCs. Third, we search these spectra for mass evidence of the
theoretical peptides. Fourth, if a potential match is found, this is
tested by targeted tandem mass spectrometry.
To evaluate this strategy we chose HIV gag p24 peptide
sequences because the gag protein plays an important role in
inducing protective T cell immunity to HIV [11] and is
consequently a component of several experimental vaccines
[3,12,13,14]. Indeed, identification of the CD4+ T cell epitopes
presented on class II MHC complexes are of particular interest
because of their role in the development of protective antibody
responses induced by vaccination [15]. We used our strategy to
identify two MHC II-bound HIV gag p24 peptides, which elicited
strong T cell responses in vitro. We also demonstrate that
presentation of MHC II-associated HIV gag peptides by mature
DCs takes place intracellularly.
Results
EpiSifter for Rapid Detection of Specific MHC II Peptides
To detect, identify and measure exogenous MHC II-bound
peptides presented by DCs among the abundant and complex
mixture of endogenous peptides, Flt3L-mobilized DCs are pulsed
in vitro with synthetic peptides or with a protein [1,7,16,17]. DC
MHC II-complexes are then enriched by immunoprecipitation,
whereupon bound peptides are eluted and purified for MS analysis
(Figure 1A) [7]. However, it is difficult to detect these specific low
abundance peptides by conventional data-dependent acquisition.
In data-dependent acquisition, the masses of all peptides eluting at
a particular time are first measured. Then, based on this
measurement, starting typically from the highest intensity peak
species, a number of peptide ions are sequentially isolated and
their fragmentation spectra (MS/MS) acquired. In highly complex
samples, as is the case for DC MHC II peptide mixture, this
method often fails to detect the less abundant species of interest
[18].
To overcome this limitation we developed a four step strategy
(Figure 1B): (I) the program EpiSifter generates all theoretical
possible MHC II peptides, ranging from 9 up to 25 amino acid in
length from the amino acid sequence of the known antigen
(peptides or protein). Their possible mass to charge (m/z) ratios
are calculated along with their isotope ratios. Typical modifica-
tions, like oxidized methionine, are also considered for calculation
of the theoretical m/z values. (II) The masses of the enriched
MHC II peptides isolated from DCs are measured with high
accuracy by LC-MS analysis. (III) Mass chromatograms of the m/
z ratios for all the theoretically possible peptides are visualized as
color-coded plots, allowing a fast and efficient checking of the
spectra. (IV) Peptides, where signals are observed at the correct m/
z ratio, have the expected chromatographic peak width and have
Figure 1. A schematic overview of the strategy to identify and
analyze MHC II peptides presented by DCs from exogenous
protein and peptide sequences. (A) MHC II peptide-complexes are
isolated by immunoprecipitation from DCs pulsed in vitro with antigen.
(B, I) A list of all possible theoretical peptides is generated from the
amino acid sequence of the known antigen. (B, II) The masses of the
enriched DC MHC II peptides are measured by LC-MS analysis. (B, III) The
mass chromatograms for the isotopic peaks of all possible theoretical
peptides are visualized as color-coded plots. (B, IV) The observed
peptide masses are selected for targeted MS/MS analysis.
doi:10.1371/journal.pone.0041897.g001
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the correct isotope distribution, are selected for targeted MS/MS
analysis in a separate run to test their sequence and identity.
Using this strategy we can rapidly find mass evidence for
putative exogenous MHC II peptides and then test their identity
by targeted MS/MS. An additional advantage of this strategy is
that it identifies the most abundant charge state for subsequent
targeted analysis, further reducing the list of candidate masses
dramatically.
Identification of DC MHC II-bound Peptides from an
Exogenous HIV gag p24 Peptide Mixture
To test the strategy, DCs were loaded with four HIV gag p24
15-mer peptides at concentrations of 1 mM each. These were
previously identified by ELISPOT assay as mimetopes after anti-
DEC gag p24 antibody vaccine immunization in two distinct
mouse haplotypes (Table 1) [3]. EpiSifter generated a list of all 321
theoretically possible peptides, 9 to 15 amino acids in length
(Table S1), for the four HIV gag 15 mer mimetope sequences by
applying the following rules: a) removing up to four amino acids
from both termini; b) allowing charge states from +1 to +4; c)
considering methionine in its oxidized and unoxidized form.
Following LC-MS analysis of DC MHC II-bound peptides [7],
the mass chromatograms were visualized with EpiSifter for each
theoretically predicted peptide (Table S1). Figure 2 and Figure S1
show the mass chromatograms for DC MHC II-bound HIV gag
p24 peptides from one representative experiment of three
biological replicates. By manual inspection of the 321 mass
chromatograms (one for each predicted peptide) we observed for
two peptide sequences, VDRFYKTLRAQASQ (D6 in Table 1)
and DRFYKTLRAQASQ (designated D6.1), a region in the mass
chromatogram where the first three isotopes of the peptide were
present at approximately the expected intensity ratios (Figure 2A
and 2B) [19]. There was no evidence in the mass chromatograms
for the other possible versions of the other three HIV gag p24
peptides added to DCs (Figure S1A, S1B, S1C). By conventional
database search of the original data, MHC II HIV gag p24
peptides could not be identified among the endogenous mouse
MHC II peptides. (Table S2) [7]. Next, we performed targeted
MS/MS analysis for the two peptides shown in Figure 2A and 2B.
Figure 2C and 2D show the MS/MS spectra of the double
charged peptides VDRFYKTLRAQASQ and DRFYKTLRA-
QASQ at m/z 906.48 and m/z 856.94 respectively. The
corresponding MS/MS spectra of MHC II-bound HIV gag p24
peptide sequences (Figure 2C and 2D) were identical to the ion
product spectra of the synthetic isotope labeled peptides
VDRFYKT*LRAQASQ (m/z 909.99, z = 2, *13C6N1 L) and
DRFYKT*LRAQASQ (m/z 860.45, z = 2, *13C6N1 L) respec-
tively (Table S3), confirming unambiguously the validity of the
identification (Figure S2).
We concluded that by using EpiSifter strategy we quickly and
successfully identified the exogenously added peptide,
VDRFYKTLRAEQASQ, and a second peptide, DRFYKL-
TRAEQASQ, derived from the original added HIV gag p24
15-mer peptide by cleavage of the N-terminal amino acid (Table 1)
(see below).
The Two MHC II-bound HIV gag p24 Peptides Presented
by DCs are Derived from a Single Exogenous Peptide
Sequence
To test that the DRFYKLTRAEQASQ peptide is indeed
derived from the original exogenously added VDRFYKLTRAE-
QASQ peptide sequence by an active physiological process, we
performed a set of experiments, the results of which are provided
in Figure 3. Figures 3A and 3B show details of the mass spectra of
VDRFYKTLRAQASQ (m/z 906.48, z = 2) and DRFYKTLRA-
QASQ (m/z 856.94, z = 2) recorded from the MHC II eluted
peptide mixture. Figure 3C and 3D show mass spectra of the
isotope pairs corresponding to VDRFYKTLRAQASQ (Figure 3C)
and DRFYKTLRAQASQ (Figure 3D) peptides when DCs were
pulsed with an equimolar mixture of heavy and light isotope forms
of HIV gag p24 VDRFYKTLRAQASQ peptide (Table S3).
Observation of these pairs supports the hypothesis that the 14-mer
peptide DRFYKTLRAQASQ is generated from the original 15-
mer peptide sequence VDRFYKTLRAQASQ added to DCs
in vitro.
To examine in more detail the processing of the exogenously
added peptides by DCs, we repeated the same experiment in the
presence of 20 mM ammonium chloride (NH4Cl) as an inhibitor
of endo-lysosome compartment acidification. In the presence of
20 mM NH4Cl, we did not detect any signal at the expected m/z
values (Figure S3A and S3B), suggesting that binding to MHC II
complexes of the HIV gag p24 peptides VDRFYKTLRAQASQ
and DRFYKTLRAQASQ occurred intracellularly and was
inhibited by 20 mM NH4Cl.
Exogenously Added HIV gag p24 Peptides are Presented
on DC MHC II Molecules in a Similar Concentration Range
as the Endogenous Self-MHC II Peptides
To evaluate the absolute abundance of MHC II-bound HIV
gag VDRFYKTLRAQASQ and DRFYKTLRAQASQ peptides
presented on DCs, we performed quantitative analysis by using
isotope labeled peptide standards [7]. Figure S4 shows the mass
chromatogram of the VDRFYKTLRAQASQ and the
DRFYKTLRAQASQ peptide pairs measured in one representa-
tive experiment. We extrapolated from three biological replicates
that the amount of VDRFYKTLRAQASQ presented on MHC II
molecules of DCs was 1964 fmol/mL, corresponding to 5906120
copies per cell. Quantitation of DRFYKTLRAQASQ peptide
showed that it was presented on DC MHC II molecules at
18006120 copies per cell, calculated from 6064 fmol/mL.
In conclusion, we observed that DCs presented exogenous HIV
gag p24 peptides on MHC II complexes in the range of
concentration detected previously for the endogenous MHC II
peptide repertoire, i.e. 2.5 fmol/mL to 12 pmol/mL or from
approximately 13 to 26105 copies per DC [7].
Identification of VDRFYKTLRAEQASQ and
DRFYKTLRAEQASQ as MHC II-bound Peptides Derived
from Processing of Anti-DEC 205-HIV gag p24 Protein by
DCs
To extend our strategy to a relevant vaccine protein delivered as
exogenous antigen, we used anti-DEC 205 HIV gag p24 protein,
Table 1. HIV gag p24 immunoreactive peptides previously
identified by ELISPOT assay.
BALB/c(I-A/Ed) A9 aa 165–179 SPEVIPMFSALSEGA
C8 aa 257–271 PVGEIYKRWIILGLN
C57BL/6 (I-Ab) A4 aa 145–159 QAISPRTLNAWVKVV
D6 aa 297–311 VDRFYKTLRAEQASQ
HIV gag p24 mimetope peptides identified previously from 15-mer peptide
pools to stimulate IFNc secretion by CD4+ T cells in two MHC haplotypes after
anti-DEC-HIV gag p24 immunization [3].
doi:10.1371/journal.pone.0041897.t001
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delivered specifically to DCs in vitro through the cell-specific DEC-
205 receptor [3,12,13,14]. We previously demonstrated that
introduction of a protein within anti-DEC-205 antibody greatly
enhances the capacity of Flt3L DCs to present an antigen, such as
for example HIV gag p24 protein [1,7,16,17]. Here, we first
pulsed mouse spleen Flt3L-DCs in vitro for 5 h with 1 mg/mL
(5 pM) of anti-DEC-205 HIV gag p24 protein and then we eluted
MHC II peptides as described above. In this case, EpiSifter
generated a list of all 8189 theoretically possible peptides, 7–27
amino acids in length (Table S4), for the HIV gag p24 protein
sequence (aa 133–363 derived from HIV isolate BH10), consid-
ering charge states from +1 to +4 and methionine oxidation.
Following LC-MS analysis of eluted DC MHC II-bound
peptides, the mass chromatograms were visualized with EpiSifter
for all the theoretically predicted peptides. Figure 4 shows the mass
chromatograms of the previously identified (Figure 2) HIV gag
p24 peptides VDRFYKTLRAEQASQ (D6) and DRFYKTL-
RAEQASQ (D6.1), as DC MHC II-bound peptides naturally
processed from the anti-DEC-205 HIV gag p24 protein added
exogenously to splenic Flt3L-DCs in vitro. We observed for the two
peptides, VDRFYKTLRAEQASQ (D6) and DRFYKTLRAE-
QASQ (D6.1) identified above, a region in the mass chromato-
gram where the first three isotopic peaks of the peptides were
present with similar predicted intensities, in two different charge
states, +3 and +4, (Figure 4A and 4B). By EpiSifter we did not
detect the other previously described HIV gag p24 mimetopes
(Table 1), in agreement with our initial observations with
exogenously added 15-mer peptides (Figure S1).
We performed MS/MS analysis on the experiment shown in
Figure 5 but we did not obtain the sequences of VDRFYKTL-
RAQASQ and DRFYKTLRAQASQ peptides. We hypothe-
sized that the sequencing could not be performed because they
were present in low amounts, thus preventing successful
fragmentation of the peptide ions. Then, to prove the identity
of VDRFYKTLRAQASQ and DRFYKTLRAQASQ peptides,
we introduced their corresponding synthetic isotopically labeled
peptides VDRFYKT*LRAQASQ (*13C6N1 L) and
DRFYKT*LRAQASQ (*13C6N1 L) (Table S3) into the sample
prior to LC-MS run. This pair of peptides (light and heavy
isotopes) is chemically identical, with the same amino acid
sequence and easily detectable because it coelutes during LC
separation. In Figure 5 we show the chromatographic profile of
a representative example of LC-MS experiment for
VDRFYKTLRAEQASQ (Figure 5A) and DRFYKTLRAE-
Figure 2. Query of DC MHC II- bound HIV gag p24 peptides derived from an exogenous peptide mixture. Full scan profile of two
predicted peptides generated by EpiSifter. The black histogram indicates the monoisotopic peak, the red one corresponds to the first 13C isotope,
while the grey-coded one represents the second. The isotope envelopes marked with arrows correspond to the peptide sequences: (A)
VDRFYKTLRAEQASQ (designated as D6) and (B) DRFYKTLRAEQASQ (designated as D6.1). (C, D) MS/MS spectra of the query peptides,
VDRFYKTLRAEQASQ (m/z 906.48, z = 2) (C) and DRFYKTLRAEQASQ (m/z 856.94, z = 2) (D).
doi:10.1371/journal.pone.0041897.g002
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QASQ (Figure 5B) isotope peptide pair. We enlarged the area
of the spectrum comprising the masses of interest to show the
extracted ion chromatographic profile of the triple charged
peptides VDRFYKTLRAEQASQ (Figure 5A) and DRFYKTL-
RAEQASQ (Figure 5B) at m/z 604.6532 (z = 3) and m/z
571.6297 (z = 3), respectively. The simultaneous detection of
peaks at m/z 604.6532 and 606.9917 (z = 3, Figure 5A)
indicated the co-elution of VDRFYKTLRAQASQ and
VDRFYKT*LRAQASQ peptides during LC separation (reten-
tion time = 50.19 minute, data not shown). We calculated as
2.1 and 1.98 ppm the mass deviation between the measured m/
z values (604.6532 and 606.9917 for VDRFYKTLRAEQASQ
and VDRFYKT*LRAQASQ, respectively) and the theoretical
values, 604.6519 and 606.9905, of the VDRFYKTLRAEQASQ
peptide pair. In other words, the exact mass measurement of
the VDRFYKTLRAEQASQ peptide pair and co-elution during
LC separation led to the unambiguous peptide assignment.
The same method was applied to confirm the presence of
peptide DRFYKTLRAQASQ in the sample. The measured m/z
of DRFYKTLRAEQASQ and DRFYKT*LRAQASQ (*13C6N1
L) peptides were 571.6297 and 573.9688 respectively with only
1.75 ppm and 1.91 ppm mass deviation (Figure 5 B), compared to
the theoretical mass, 571.6287 and 573.9677, calculated respec-
tively for DRFYKTLRAEQASQ and DRFYKT*LRAQASQ
peptide sequences.
Last, the MS/MS spectra obtained for the synthetic isotope
labeled peptide VDRFYKT*LRAQASQ at m/z 606.9917, z = 3
and for DRFYKT*LRAQASQ at m/z 573.9688, z = 3 are shown
in Figure 5C and 5D, respectively. Their MS/MS sequences
further confirmed the validity of the identification of
VDRFYKTLRAEQASQ at m/z 604.6532 (Figure5A and 5C)
and DRFYKTLRAEQASQ at m/z 571.6297 (Figure 5B and 5D)
as DC MHC II-bound peptides derived from anti-DEC-205 HIV
gag p24 protein exogenously added to mouse splenic DCs. Taken
together the above data provide strong support for the presence of
naturally processed VDRFYKTLRAEQASQ (D6) and
DRFYKTLRAEQASQ (D6.1) MHC II-associated peptides de-
rived from anti-DEC 205 HIV gag p24 protein.
We concluded that by using EpiSifter strategy we quickly and
successfully identified two peptides, VDRFYKTLRAEQASQ and
DRFYKLTRAEQASQ as naturally processed DC MHC II-
bound peptides derived from the exogenously added anti-DEC-
205 HIV gag p24 protein. In addition, these data validated our
findings with exogenously added VDRFYKTLRAEQASQ (D6)
HIV gag p24 peptide identified in the first part of our work
(Figure 2).
Figure 3. Detection of VDRFYKTLRAEQASQ and DRFYKTLRAEQASQ as DC MHC II-bound peptides after DCs were pulsed in vitro
with VDRFYKTLRAEQASQ HIV gag p24 peptide sequence. (A) MS profile of the VDRFYKTLRAEQASQ peptide identified in the MHC II peptide
mixture eluted from one representative sample. (B) MS profile of the DRFYKTLRAEQASQ identified from the same sample as in A. (C) MS profile of the
VDRFYKTLRAEQASQ isotope pair eluted from DCs pulsed with an equimolar ratio of heavy and light VDRFYKTLRAEQASQ peptide (Table S3). (D) MS
profile of the DRFYKTLRAEQASQ peptide pair identified from the same sample as in (C). Isotope peaks corresponding to m/z (z = 2) values for the
detected peptides are shown in the shaded area. Heavy isotope peaks are marked with a (*).
doi:10.1371/journal.pone.0041897.g003
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DCs Display Low Amounts of Processed MHC II Peptides
from Anti-DEC-205 HIV gag p24 Protein
We extracted quantitative data for the HIV gag p24
VDRFYKTLRAEQASQ (D6) and DRFYKLTRAEQASQ
(D6.1) peptides derived from anti-DEC-205 HIV gag p24 protein
in the experiment described in Figure 5. By using a known amount
(1 ng) of isotopically labeled peptides standards [7], from a single
quantitation analysis (Figure 5), we measured 1.4 fmol/mL of
VDRFYKTLRAEQASQ (D6) and 0.14 fmol/mL of DRFYKTL-
RAEQASQ (D6.1), corresponding approximately to 17 and 1.6
copies/cell, respectively. As a control in the same experiment, we
quantitated the amount of KELEEQLGPVAEETR MHC II
peptide derived from endogenous apolipoprotein E [7], to be 180
copies/cell (15 fmol/mL) (Figure S5). This measurement is in good
agreement with our previous quantitation of 548 copies per cell
(42 fmol/mL) [7]. It falls within the 30% range of variability
tolerated when different biological samples and different analytical
runs are compared [20]. However, the values obtained for the
VDRFYKTLRAEQASQ (D6) and of DRFYKTLRAEQASQ
(D6.1) peptides presented on MHC II molecules on DCs may be
an underestimation due to large differences in the peak intensities
between the MHC II-bound peptides and the isotopically labeled
standards added in the sample prior to the MS run.
Ag-specific CD4+ T Cells Recognize MHC II-bound HIV
gag Peptides Identified by LC-MS/MS
To determine the reactivity of VDRFYKTLRAQASQ and
DRFYKTLRAQASQ MHC II- bound HIV gag p24 peptides
identified with the present strategy, we performed 6-carboxy-
fluorescein succinimidyl ester (CFSE) T cell proliferation assays.
Figure 4. Query of DC MHC II- bound peptides derived from exogenously added anti-DEC-205 HIV gag p24 protein. (A, B) Full scan
profile of VDRFYKTLRAEQASQ (D6) and DRFYKTLRAEQASQ (D6.1) peptides generated by EpiSifter. The isotope envelopes marked with arrows
correspond to the previously identified peptide sequences: (A) VDRFYKTLRAEQASQ (D6) and (B) DRFYKTLRAEQASQ (D6.1), both found in the +3 and
+4 charge states.
doi:10.1371/journal.pone.0041897.g004
MS Analysis to Identify CD4 T Cell Epitopes on DCs
PLoS ONE | www.plosone.org 6 July 2012 | Volume 7 | Issue 7 | e41897
MS Analysis to Identify CD4 T Cell Epitopes on DCs
PLoS ONE | www.plosone.org 7 July 2012 | Volume 7 | Issue 7 | e41897
Synthetic VDRFYKTLRAQASQ and DRFYKTLRAQASQ
HIV gag p24 peptides were added to bulk splenocytes isolated
from HIV gag p24 immunized mice [21]. In Figure 6A, we
measured proliferation and IFNc production in the presence of
HIV gag p24 VDRFYKTLRAQASQ (D6) and DRFYKTLRA-
QASQ (D6.1) peptides. We observed that CD4+ T cells
proliferated actively after restimulation with VDRFYKTLRA-
QASQ and DRFYKTLRAQASQ peptides as well as in presence
of the 56-peptide mixture spanning the entire HIV gag p24
sequence (Figure 6A). No reactivity was measured with the
negative control HIV gag p17 peptide mix [3] and with the
endogenous MHC II apolipoprotein E (ApoE) peptide, which
sequence is shown in Figure S5 [7].
We also compared the reactivity of VDRFYKTLRAQASQ
peptide with the other three HIV gag p24 mimetopes (Table 1),
which were not detected by LC-MS as MHC II-bound peptides
(Figure S1). Only the HIV gag p24 VDRFYKTLRAQASQ
peptide stimulated efficiently proliferation and IFNc secretion of
HIV p24 specific CD4+ T cells, comparably to the response with
the 56-peptide mix HIV gag p24 (Figure S6). None of the other
HIV gag p24 mimetopes were reactive in expanding antigen-
specific bulk splenocytes.
Next, to directly assess the function of DCs in presenting the
above-identified HIV gag p24 VDRFYKTLRAQASQ (D6) and
DRFYKTLRAQASQ (D6.1) peptides to T cells, peptide pulsed
DCs were cocultured with a fixed number of T cells isolated from
HIV gag p24 immunized mice [21]. T cell proliferation and IFNc
Figure 5. Detection of VDRFYKTLRAEQASQ (D6) and DRFYKTLRAEQASQ (D6.1) as DC MHC II-bound peptides after DCs were
pulsed in vitro with anti-DEC-205 HIV gag p24 protein. One representative experiment of two biological replicates is shown. MS profile of
VDRFYKTLRAEQASQ (D6) (A) and DRFYKTLRAEQASQ (D6.1) (B) isotope peptide pair identified as MHC II-bound peptides derived from anti-DEC-205
HIV gag p24 protein, using synthetic isotopically labeled peptides as internal standards, marked with (*). For clarity, the restricted mass range of
interest was zoomed in. (C, D) Identification of MHC II-bound peptides from anti-DEC-205 HIV gag p24 protein. MS/MS spectra were obtained for the
synthetic isotope labeled peptides at m/z 606.9917, z = 3 for VDRFYKT*LRAQASQ (C) and at m/z 573.9688, z = 3 for DRFYKT*LRAQASQ (D) recorded in
the LC-MS analysis shown in Figure 5A and 5B. The isotopically labeled amino acid is labeled with a (*). The corresponding y and b series are marked.
doi:10.1371/journal.pone.0041897.g005
Figure 6. Immuno-reactivity of the MHC II-bound HIV gag p24 peptides measured by FACS analysis. (A) CFSE-labeled bulk splenocytes
from HIV gag p24 immunized mice were stimulated with negative control HIV gag p17 peptide mix, positive control HIV gag p24 peptide mix and HIV
gag VDRFYKTLRAEQASQ (D6), DRFYKTLRAEQASQ (D6.1) peptides and unrelated ApoE peptide (Figure S5). (B) Antigen presentation assay of MHC II–
bound HIV gag p24 peptides in DC:T cell cocultures. Untreated (medium) and CQ-treated DCs were loaded with graded doses of peptides and added
to CFSE-labeled purified T cells. Values represent mean 6 SD of the percentage of CD4+ IFNc+ T cells pooled from four independent experiments.
Paired Student’s t-test was performed for untreated- versus CQ-treated DCs.
doi:10.1371/journal.pone.0041897.g006
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secretion were measured as above. We used a T cell: DC ratio of
20:1, at which only minimal level of unspecific T cell proliferation
was detected. We observed a robust proliferation and cytokine
secretion of CD4+ T cells when DCs were pulsed with graded dose
of VDRFYKTLRAEQASQ (D6) and DRFYKTLRAEQASQ
(D6.1) peptides (Figure 6B, left ‘‘medium’’ chart). And as expected
no T cell activation was induced when DCs were pulsed with
unspecific peptides (HIV gag p17).
Several reports have suggested that binding of exogenous
mimetope peptides to MHC molecules may occur at the cell
surface, without the need for intracellular processing [22]. Other
reports have indicated that binding of exogenous peptides may
take place intracellularly upon uptake of the peptides [23]. To
begin to understand the mechanism of processing and presentation
of exogenous peptides by DCs, we inhibited endosomal-lysosomal
system acidification with chloroquine (CQ). In control experiments
we first determined the optimal concentrations of CQ by using DC
viability as an endpoint. Treatment of DCs with 100 mM CQ did
not alter cell viability compared to untreated cells (1.86106 and
1.76106, respectively, recovered from initial 26106 DC/well).
Since treatment with CQ distinctly inhibited T cell-activation by
DCs in response to HIV gag p24 peptides, we inferred that
intracellular processing of exogenously added VDRFYKTLRA-
QASQ was required, (Figure 6B, right ‘‘CQ’’ chart). In four
independent experiments CD4+ T cell activation to peptide-
loaded DCs was decreased by a median of 26% for VDRFYKTL-
RAQASQ (p = 0.038 compared to peptide alone at 1 mg/ml) and
46% for DRFYKTLRAQASQ peptide (p = 0.012 compared to
peptide alone at 1 mg/ml). In line with other reports [24,25], we
found that inhibition of peptide presentation by NH4Cl was
reversible after removal of NH4Cl by extensive washing of DCs
with PBS (Figure S7). All together these results demonstrate that
low concentrations of MHC II-associated HIV gag p24
VDRFYKTLRAQASQ and DRFYKTLRAQASQ peptides in-
duce expansion of antigen-specific CD4+ T cells and that MHC II
presentation of 15- or 14-mer peptides by mature DCs occurs
through intracellular pathways.
Finally, we assessed the functional avidity of T cell responses
following VDRFYKTLRAEQASQ and DRFYKTLRAEQASQ
peptides presentation by DCs [26]. The magnitude of the CD4+ T
cell response measured for each peptide concentration from
Figure 6B was expressed as a percentage of the maximum response
observed with 161026 M peptide (Figure S8). The EC50,
calculated as estimation of functional avidity indicated that
VDRFYKTLRAEQASQ and DRFYKTLRAEQASQ peptides,
presented on MHC II molecules of DCs, have similar sensitivity
for antigen-specific T cells (EC50 3.7 and 3.6610
28 M, respec-
tively). For comparison, a 30 fold higher concentration of Her2
derived peptide, PDSLRDLSVF, amino acid 420–429, from the
Her2/Neu breast cancer antigen [27] is required to induce
antigen-specific T cell responses in a vaccine model for breast
cancer [28]. The measured high avidity of T cells specific to HIV
gag p24 VDRFYKTLRAEQASQ and DRFYKTLRAEQASQ
peptides reinforces the use of the HIV gag p24 protein as a vaccine
target in clinical studies.
Discussion
We have described a strategy, which combines the use of a
computational tool, EpiSifter, with LC-MS analysis, to identify
antigen-specific MHC II peptides eluted from DCs. To test the
strategy, we first used DCs that were pulsed in vitro with HIV gag
p24 peptides and we identified two MHC II-bound HIV gag p24
sequences, VDRFYKTLRAQASQ and DRFYKTLRAQASQ,
present at concentrations within the range of previously identified
MHC II self-peptides on DCs [7]. For the reasons we discussed
earlier, traditional data-dependent LC-MS/MS analysis was
unable to identify (Table S2), these sequences and this limitation
was overcome by the present strategy (Figure 1B).
There have been only few reports of exogenous MHC-bound
peptides identified by LC-MS/MS analysis, and only following
exhaustive manual interrogation of thousands of MS/MS spectra
or by prior peptide fractionation of complex mixture followed by
screening of antigenic peptide fractions in T cell assays
[4,29,30,31,32]. The benefit of our strategy is that it depends in
the first instance on the acquisition of accurate mass measurements
that narrow the potential m/z values, which are compatible with
predicted peptides. The EpiSifter predicts all possible candidate
peptides and uses an effective graph representation to target only
those peptide masses that are actually detected. Then, targeted MS
sequencing is performed for the candidate peptides that are
initially best revealed by the program (Figure 1B). This strategy is
particularly useful for the analysis of unanticipated peptide species
where other techniques such as selected reaction monitoring
(SRM) or targeted analyses are not feasible.
In the initial experiments (Figure 2) we used VDRFYKTLRA-
QASQ (D6) and other three HIV gag p24 mimetope sequences
(Table 1) as a proof of concept. However, this strategy is applicable
to any other protein sequence. Indeed, we extended our approach
and evaluated antigen processing following exogenous pulsing of
mouse spleen DCs with a relevant vaccine protein, such as anti-
DEC-205 HIV gag p24. We successfully demonstrated that
VDRFYKTLRAQASQ (D6) and DRFYKTLRAQASQ (D6.1)
peptides are two naturally processed epitopes from the entire HIV
gag p24 protein (Figure 4 and 5), when delivered to DCs through
the DEC-205 receptor [3,12,13,14]. We found that DCs display
relatively small amounts of naturally processed VDRFYKTLRA-
QASQ (D6) and DRFYKTLRAQASQ (D6.1) MHC II peptides
derived from anti-DEC-205 HIV gag p24 protein (Figure 5).
Nonetheless, the identified MHC II-associated HIV gag p24
peptides elicited strong dose-dependent responses from antigen
specific CD4+ T cells, which have acquired high avidity for these
MHC II-bound peptides as a result of the immunization with anti-
DEC 205-HIV gag p24 protein (Figure 6 and Figure S8) [33].
These observations are consistent with previously published work
suggesting that T cell activation correlates inversely with the
number of MHC complexes of cognate peptide per DC and that
very few MHC-peptide complexes are necessary for the induction
of full-fledged T cell activation [34,35,36].
As demonstrated above, a major advantage of the described
strategy is the ability to identify distinct MHC-bound peptides
from antigenic, vaccine proteins. In the experiments presented in
this manuscript we focused our efforts on identifying the two
immunodominant (D6) and DRFYKTLRAQASQ (D6.1) peptides
derived from the HIV gag p24 protein. Future experiments will
examine whether additional peptides derived from the exogenous-
ly added DEC-205 HIV gag p24 protein are presented on mouse
spleen DCs following the delivery of the HIV gag p24 protein
through the DEC-205 receptor.
When VDRFYKTLRAQASQ peptide was added exogenously
to DCs in vitro its presentation required intracellular processing
(Figure 3C and 6B), suggesting an active role of DCs in generating
MHC II-bound peptides from an exogenous peptide source
[23,37] and not a direct binding of peptides to HLA molecules at
the cell surface [22,38]. Three out of the four HIV gag p24
mimetopes, added exogenously, were not detected by LC-MS/MS
(Figure S1) and did not elicit proliferation of CD4+ T cells
measured by a CFSE dilution assay (Figure S6).
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Application of MS analysis for identification of antigen-derived
peptides presented on HLA molecules is becoming a major focus
of vaccine development [32]. Naturally processed and presented
peptides can be used as vaccine candidates - either as multi
epitope-based vaccine [11] or DC-based vaccine candidates
[12,13,39] – which offer the advantages of high immunogenicity
and valuable efficacy [40]. Recently, Ranasinghe et al. reported
that an extended HIV gag D6 peptide sequence, YVDRFYKTL-
RAQASQEV (amino acid 296–313), was frequently recognized
among HIV infected subjects (40% of responders) and associated
with spontaneous control of disease progression, independently of
the patient HLA haplotype [41]. Furthermore, it has been
demonstrated that sequence conservation in this region results in
a high degree of cross-clade CD4+ T cell recognition [42] and
elicits high avidity CD4+ T cells [33].
In conclusion, the present strategy promises to assist vaccine
research by facilitating the identification and selection of vaccine-
derived epitopes. The direct characterization of T cell epitopes
opens up a powerful new approach to assess the efficacy of
different vaccination strategies, formulations, antigenic inserts and
adjuvants as well as new robust method for clinical trial
monitoring. This advance will allow us to correlate the peptide
repertoire presented on DCs with the repertoire of T cell responses
elicited in vaccine recipients [12]. In turn, this understanding
should lead to an accelerated rational design of clinical HIV
vaccine.
Materials and Methods
Detailed materials and methods are provided in Materials
and Methods S1.
Ethics Statement
All procedures were approved by the Institutional Animal Care
and Use Committee (IACUC) at The Rockefeller University, New
York (Approval ID numbers 11478 and 11460). Balb/c6C57Bl/6
(I-Ab,d/Ed) F1 mice were used in this study. Animals were
maintained under specific pathogen-free conditions and used at 6–
8 wk of age in accordance with the IACUC guidelines.
Cell Preparation
CD11c+ DCs were obtained from Flt3L-treated Balb/
c6C57Bl/6 (I-Ab,d/Ed) F1 mice [7,16]. Total 20–306106 purified
DC per well were pulsed with 1 mM of synthetic 15-mer peptides
or 1 mg/ml (5 pM) of anti-DEC-205 HIV gag p24 protein for 5–
6 h. Twenty five mg/mL polyinosinic:polycytidylic acid (poly IC)
was also added as a maturation stimulus. In some experiments,
20 mM of NH4Cl or 100 mM CQ was used to preincubate DCs.
Treated and untreated DCs were loaded with peptides.
Affinity Purification of MHC II-peptide Complexess and
Peptides Purification
MHC II molecules were purified by immunoaffinity from cell
lysate [7]. The MHC II peptide complexes were eluted with 10%
acetic acid [7]. Purified MHC II peptides were dried and
reconstituted in 20 mL 0.1% TFA/water. Half of the peptide
mixture (3.5–46108 cell equivalents) was injected for LC-MS
analysis.
LC-MS Analysis
We used a Dionex U3000 capillary/nano-HPLC system
(ThermoFisher Scientific, San Jose, CA) interfaced with the
Thermo Fisher LTQ-Orbitrap mass spectrometer, operated in a
data-dependent acquisition mode cycling through a single MS full-
scan (620–1200 m/z, 30,000 resolution) followed by 6 MS/MS
scans in the ion trap [7].
EpiSifter
EpiSifter was implemented using Perl (www.perl.org) and R
(www.r-project.org). First, sequences of the proteins of interest are
cut to generate all possible MHC II peptides, and corresponding
m/z’s are calculated for charge states +1 to +4, considering
oxidized and unoxidized methionine. Second, the mass chromato-
grams for the possible peptides, modifications, charge states, and
isotopic peaks, and interfering peaks are extracted from the data
within the mass accuracy of the mass spectrometer (10 ppm).
Third, the mass chromatograms are plotted together with the
expected intensity ratio’s using R.
Quantitation of MHC II Peptides
MHC II peptide mixture (10 mL) in 0.1% TFA/water was
mixed with 10 mL of a solution containing known amounts (1 ng)
of the two synthetic isotope labeled peptides dissolved in 50%
acetonitrile/0.1% TFA/water. The entire peptide mixture was
subjected to LC-MS analysis [7].
T Cell Cultures
Antigen-specific bulk splenocytes were isolated from F1 mice
primed intraperitoneally with 5 mg anti-DEC-205 HIV gag p24
protein and 50 mg of polyinosinic-polycytidylic acid stabilized with
polylysine and carboxymethylcellulose (poly ICLC), as adjuvant,
and boosted under the same condition 4–6 weeks later [21].
Spleens from immunized mice (2–4 mice) were collected 2 weeks
later after boost. CFSE-labeled bulk splenocytes were cultured
with either 0.05 mg/ml of HIV gag p24 peptide mix, HIV gag D6
and D6.1 peptides, HIV gag p17 or ApoE peptide (KE-
LEEQLGPVAEETR) [7]. For DC:T cell cocultures, 26106
splenic CD11c+ DCs were pulsed with poly IC and different
HIV gag p24 peptide concentrations. NH4Cl-, CQ-treated or
untreated DCs were loaded with peptides, washed and added to
CFSE labeled HIV gag p24 primed T cells. After 4 days of
culture, cell proliferation and cytokine production were deter-
mined by intracellular cytokine staining and FACS analysis.
Supporting Information
Figure S1 Query of DC MHC II- bound HIV gag p24
peptides after DCs were pulsed in vitro with a peptide
mixture. Panels A, B and C show the full scan generated by
EpiSifter for the 3 HIV gag mimetopes (Table 1). Note that no
signals with correct m/z and isotope distribution ratios were
detected (compare to Figure 2).
(PPTX)
Figure S2 Identification of MHC II-bound HIV gag p24
peptides. Comparison of MS/MS spectra of eluted HIV gag p24
peptides VDRFYKTLRAEQASQ (m/z 906.4745, z = 2,
Figure 3A) (A) and DRFYKTLRAEQASQ (m/z 856.9398,
z = 2, Figure 3B) (B) with MS/MS spectra of the corresponding
synthetic isotopically labeled peptides (m/z 909.9822, z = 2, Table
S3) (C) and (m/z 860.4479, z = 2, Table S3) (D). The isotopically
labeled amino acid is labeled with a (*). The corresponding y and b
series are marked.
(PPTX)
Figure S3 NH4Cl inhibits MHC II- binding of HIV gag
p24 peptides VDRFYKTLRAQASQ and DRFYKTLRA-
QASQ. (A, B) The same experiment as in Figure 3A and 3B was
performed in the presence of 20 mM of NH4Cl. No peptide ions
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(m/z = 906.4736 and m/z = 856.9394) corresponding to the
peptides above could be detected.
(PPTX)
Figure S4 Quantitation of MHC II-associated
VDRFYKTLRAEQASQ and DRFYKTLRAEQASQ HIV
gag p24 peptides. Heavy isotopes peaks are indicated with a
(*). MS profile of VDRFYKTLRAEQASQ (A) and DRFYKTL-
RAEQASQ (B) isotope peptide pair identified as MHC II-bound
peptides. The detected m/z values are indicated in bold letters.
(PPTX)
Figure S5 Quantitation analysis of a selected endoge-
nous MHC II peptide. Heavy isotopes peaks are indicated with
a (*). MS profile of the ApoE isotope peptide pair (KE-
LEEQL*GPVAEETR, mass shift 1727.88+7 Da) identified in
the MHC II peptide mixture eluted from the experiment shown in
Figure 5. The detected m/z values are indicated in bold letters.
(PPTX)
Figure S6 Immuno-reactivity of HIV gag p24 mime-
topes measured by FACS analysis. CFSE-labeled bulk
splenocytes from HIV gag p24 immunized mice were stimulated
with negative control HIV gag p17 peptide mix, positive control
HIV gag p24 peptide mix and with the four HIV gag p24
mimetopes listed in Table 1.
(PPTX)
Figure S7 Presentation of HIV gag p24 VDRFYKTL-
RAEQASQ peptide in DC:T cell cocultures. Untreated
(medium) and NH4Cl-treated DCs, prepared from the experiment
described in Figure 3A and 3C, were loaded with graded doses of
VDRFYKTLRAEQASQ peptide, washed with PBS and added to
CFSE-labeled purified T cells. Values represent mean 6 SD of the
percentage of CD4+ IFNc+ T cells pooled from two independent
experiments.
(PPTX)
Figure S8 Functional avidity of MHC II–bound HIV gag
p24 peptides in DC:T cell cocultures. For each peptide
concentration (2logM), the frequencies of CD4+ IFNc+ T cells
measured in (Figure 6B) were expressed as percentage of the
maximum response obtained at saturation (161026 M). The
indicated EC50 represents the peptide concentration of
VDRFYKTLRAEQASQ and DRFYKTLRAEQASQ peptides,
respectively, required to attain 50% of maximal IFNc production
by HIV gag p24 specific CD4+ T cells.
(PPTX)
Table S1 List of all theoretically predicted peptides, m/
z ratios and relative intensities for the isotope distribu-
tions, calculated by EpiSifter from the HIV gag p24
mimetope sequences shown in Table 1.
(XLS)
Table S2 List of identified DC MHC II-bound peptides.
Peptide sequences were analyzed by tandem MS and identified by
searching the IPI database for mouse protein sequences plus the
HIV gag p24 protein sequence using the X! Tandem algorithm
(see Materials and Methods), allowing for enzymatic cleavage
between any pair of amino acids. Only peptides with mass
accuracy better than 20 ppm and 0.4 Da for precursors and
fragments, respectively, were included.
(XLS)
Table S3 List of isotope labeled peptides synthesized
for quantitation analysis and their MS parameters.
(a)Mass corresponds to the monoisotopic form of the selected
peptide. (b)Predicted mass shift due to the incorporation of the
isotopically labeled amino acid.
(DOCX)
Table S4 List of all theoretically predicted peptides, m/
z ratios and relative intensities for the isotope distribu-
tions, calculated by EpiSifter from the HIV gag p24
protein sequence (aa 133–363 derived from HIV isolate
BH10).
(XLSX)
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